Development of new active pharmaceutical ingredients (APIs) is lengthy and cost-intensive, thus avoiding any potential risk that may limit the product’s success is of utmost importance. Today, many APIs are not being commercialized as they are poorly water soluble (BCS class II and IV) and, as a result, exhibit too low bioavailability. Diverse API processing techniques have evolved to be chosen to improve drug solubility, but also stability and processability. Learn in which cases salt or cocrystal formation are your techniques of choice, how to find the right coformers for your API, and how to avoid the obstacles – so that you can care about commercialization, not solubilization.
In this webinar, you will learn:
Thomas Briel, Ph.D.
Strategic Marketing Manager, Excipients Liquid Application
Thomas Briel is strategic marketing manager at MilliporeSigma and responsible for a broad portfolio of excipients for liquid formulation. He has more than 6 years of experience in the pharma and biopharma industry with different positions in the field of pharmaceutical formulation. Thomas holds a Ph.D. in biology from the Technical University of Munich. In parallel to his Ph.D. and industry roles, Thomas acquired a B.S. in economics with a focus on marketing.
David Luedeker, Ph.D.
Principal Scientist - Solid Formulation
David Luedeker is a principal scientist at MilliporeSigma, working in the solid formulation R&D group supporting the development of novel excipients. David holds a Ph.D. in Chemistry from the University of Münster, dealing with the screening and analytics of pharmaceutical cocrystals and salts. He has more than 4 years of industrial experience in the pharmaceutical industry, focusing on the characterization of active compounds and stabilization techniques for solid oral dosage formulations.
To continue reading please sign in or create an account.Don't Have An Account?